Lengthening Adalimumab Dosing Interval in Quiescent Crohn's Disease Patients (LADI)
Sponsor: Erasmus Medical Center
This PHASE4 trial investigates Crohn Disease and Crohn Disease in Remission and is currently ongoing. Erasmus Medical Center leads this study, which shows 14 recorded versions since 2017 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
14 versions recorded-
Sep 2025 — Present [monthly]
Unknown PHASE4
-
Sep 2024 — Sep 2025 [monthly]
Unknown PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE4
Status: Unknown Status → Unknown
-
Dec 2023 — Jul 2024 [monthly]
Unknown Status PHASE4
Status: Active Not Recruiting → Unknown Status
-
Nov 2022 — Dec 2023 [monthly]
Active Not Recruiting PHASE4
Status: Unknown Status → Active Not Recruiting
▶ Show 9 earlier versions
-
Sep 2022 — Nov 2022 [monthly]
Unknown Status PHASE4
Status: Active Not Recruiting → Unknown Status
-
Mar 2022 — Sep 2022 [monthly]
Active Not Recruiting PHASE4
-
Jan 2021 — Mar 2022 [monthly]
Active Not Recruiting PHASE4
-
Oct 2020 — Jan 2021 [monthly]
Active Not Recruiting PHASE4
Status: Recruiting → Active Not Recruiting
-
Mar 2020 — Oct 2020 [monthly]
Recruiting PHASE4
-
Oct 2018 — Mar 2020 [monthly]
Recruiting PHASE4
-
Jun 2018 — Oct 2018 [monthly]
Recruiting PHASE4
-
Sep 2017 — Jun 2018 [monthly]
Recruiting PHASE4
-
Jul 2017 — Sep 2017 [monthly]
Recruiting PHASE4
First recorded
May 2017
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Erasmus Medical Center
- Radboud University Medical Center
For direct contact, visit the study record on ClinicalTrials.gov .